Arkolith/Insider Trading/XLO/Form 4

Frankenfield Christopher James

Chief Financial OfficerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Jan 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Sell(S)7K$0.64$4K25K
Jan 1, 2026Option exercise(M)19K——32K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 1, 2026Option exercise(M)19K—$039K
Dec 31, 2025Grant(A)669K—$0669K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-002517) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML